Atlas Trials

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Clinical trial NCT04827810 · RECRUITING

Trial details

NCT number
NCT04827810
Sponsor
Fox Chase Cancer Center
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
LymphomaAdvanced Solid Tumor
Start date
2021-11-05
Primary completion
2026-06-30
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.